Dermatological aspects of angiogenesis.
Neovascularization is vital for the growth of tumours, providing a lifeline for sustenance and waste disposal. Tumour vessels can grow by sprouting, intussusception or by incorporating bone marrow-derived endothelial precursor cells into growing vessels. Recent advances in vascular biology have identified some key factors that control vascular growth, and have led to the hypothesis that in normal tissues vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. In contrast, increased secretion of angiogenic factors and the down-regulation of endogenous angiogenesis inhibitors induce tumour angiogenesis. Vascular quiescence in the skin seems to be primarily maintained by a balance between the endogenous angiogenesis inhibitors thrombospondin 1 and thrombospondin 2 and the potent proangiogenic factor vascular endothelial growth factor A. Inhibiting tumour growth by controlling angiogenesis is an intriguing approach with great potential for the treatment of vascular tumours such as haemangioma, Kaposi's sarcoma and solid cutaneous tumours such as squamous cell carcinoma, melanoma and basal cell carcinoma. In this review, the role of angiogenesis and more recent topics such as lymphangiogenesis in cutaneous tumour growth, invasion and metastasis will be discussed.
Velasco
P
P
Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany.
Lange-Asschenfeldt
B
B
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000098:blood supply; D006801:Humans; D008545:Melanoma / Q000098:blood supply; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology*; D012878:Skin Neoplasms / Q000098:blood supply* / Q000188:drug therapy
D020533:Angiogenesis Inhibitors